|
"yen c j"的相關文件
顯示項目 181-205 / 471 (共19頁)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2021-01-14T06:25:59Z |
Seroprevalence of hepatitis B viral markers among freshmen - 20 years after mass hepatitis B vaccination program in Taiwan
|
Chang H.-C.; Yen C.-J.; Lee Y.-C.; Chiu T.-Y.; CHYI-FENG JAN |
| 臺大學術典藏 |
2021-01-12T03:32:35Z |
Age-associated changes in interferon-γ and interleukin-4 secretion by purified human CD4+ and CD8+ T cells
|
Yen C.-J.;Shuei-Liong Lin;Huang K.-T.;Lin R.-H.; Yen C.-J.; SHUEI-LIONG LIN; Huang K.-T.; Lin R.-H. |
| 臺大學術典藏 |
2021-01-12T03:32:35Z |
Effects of age and diabetes on blood flow rate and primary outcome of newly created hemodialysis arteriovenous fistulas
|
SHUEI-LIONG LIN; Huang C.-H.; Chen H.-S.; Hsu W.-A.; Yen C.-J.; Yen T.-S. |
| 臺大學術典藏 |
2021-01-12T03:32:23Z |
Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients
|
Lin Y.-F.; Chen Y.-M.; Hung K.-Y.; Chu T.-S.; Kan W.-C.; Huang C.-Y.; SHUEI-LIONG LIN; Kao T.-W.; Huang J.-W.; Chiang W.-C.; Yen C.-J.; Tsai T.-J.; Wu K.-D.; Wu M.-S. |
| 國立成功大學 |
2021 |
Comparing the clinicopathological characteristics of combined hepatocellular–cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification
|
Yen, C.-C.;Yen, C.-J.;Shan, Y.-S.;Lin, Y.-J.;Liu, I.-T.;Huang, Huang H.-Y.;Yeh, M.M.;Chan, S.-H.;Tsai, H.-W. |
| 國立成功大學 |
2021 |
No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol
|
Shan, Y.-S.;Chen, L.-T.;Wu, C.-H.;Chang, Y.-F.;Lee, C.-T.;Chiang, N.-J.;Chao, Y.-J.;Yen, C.-J.;Tsai, H.-J.;Huang, Huang H.-E.;Tsai, C.-R.;Weng, Y.-L.;Yang, H.-C.;Liu, H.-C.;Chang, J.S. |
| 國立成功大學 |
2021 |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah, H.-S.;Chiang, N.-J.;Lin, C.-C.;Yen, C.-J.;Tsai, H.-J.;Wu, S.-Y.;Su, W.-C.;Chang, K.-Y.;Wang, C.-C.;Chang, J.-Y.;Chen, L.-T. |
| 國立成功大學 |
2021 |
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
|
Kudo, M.;Galle, P.R.;Brandi, G.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Llovet, J.M.;Assenat, E.;Merle, P.;Chan, S.L.;Palmer, D.H.;Ikeda, M.;Yamashita, T.;Vogel, A.;Huang, Y.-H.;Abada, P.B.;Yoshikawa, R.;Shinozaki, K.;Wang, C.;Widau, R.C.;Zhu, A.X. |
| 國立成功大學 |
2021 |
Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
|
Lai, H.-Y.;Tsai, H.-H.;Yen, C.-J.;Hung, L.-Y.;Yang, C.-C.;Ho, C.-H.;Liang, H.-Y.;Chen, F.-W.;Li, C.-F.;Wang, J.-M. |
| 國立成功大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, T.-J.;Su, Y.-Y.;Yang, S.-H.;Li, C.-P.;Bai, L.-Y.;Chiang, N.-J.;Chuang, S.-C.;Shan, Y.-S.;Chan, D.-C.;Chen, L.-T.;Yen, C.-J.;Peng, C.-M.;Chen, Y.-Y.;Chen, J.-S.;Chou, W.-C. |
| 國立成功大學 |
2021 |
Ramucirumab for patients with intermediate-stage hepatocellular carcinoma and elevated alpha-fetoprotein: Pooled results from two phase 3 studies (REACH and REACH-2)
|
Kudo, M.;Finn, R.S.;Morimoto, Morimoto M.;Rau, K.-M.;Ikeda, M.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Daniele, B.;Lim, H.Y.;McIlwain, D.W.;Yoshikawa, R.;Nakamura, K.;Liang, K.;Wang, C.;Abada, P.;Widau, R.C.;Zhu, A.X. |
| 國立成功大學 |
2021 |
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
|
Ryoo, B.-Y.;Cheng, A.-L.;Ren, Z.;Kim, T.-Y.;Pan, H.;Rau, K.-M.;Choi, H.J.;Park, J.-W.;Kim, J.H.;Yen, C.J.;Lim, H.Y.;Zhou, D.;Straub, J.;Scheele, J.;Berghoff, K.;Qin, S. |
| 國立成功大學 |
2021 |
The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors – A Single-Center Experience
|
Tsai, H.-J.;Hsiao, C.-F.;Chang, J.S.;Chen, L.-T.;Chao, Y.-J.;Yen, C.-J.;Shan, Y.-S. |
| 國立成功大學 |
2021 |
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
|
Chang, K.-Y.;Chiang, N.-J.;Wu, S.-Y.;Yen, C.-J.;Chen, S.-H.;Yeh, Yeh Y.-M.;Li, C.-F.;Feng, X.;Wu, K.;Johnston, A.;Bomalaski, J.S.;Wu, B.-W.;Gao, J.;Subudhi, Subudhi S.K.;Kaseb, A.O.;Blando, J.M.;Yadav, S.S.;Szlosarek, P.W.;Chen, L.-T. |
| 國立成功大學 |
2021 |
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study
|
Harding, J.J.;Yang, T.-S.;Chen, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Ho, C.-L.;Huang, W.-T.;El, Dika I.;Akce, M.;Tan, B.;Cohen, S.A.;Meyer, T.;Sarker, D.;Lee, D.-W.;Ryoo, B.-Y.;Lim, H.Y.;Johnston, A.;Bomalaski, J.S.;O’Reilly, E.M.;Qin, S.;Abou-Alfa, G.K. |
| 國立成功大學 |
2021 |
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-na�ve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial
|
Adkins, D.R.;Lin, J.-C.;Sacco, A.;Ley, J.;Oppelt, P.;Vanchenko, Vanchenko V.;Komashko, N.;Yen, C.-J.;Wise-Draper, T.;Lopez-Picazo, Gonzalez J.;Radulovic, S.;Shen, Q.;Thurm, H.;Martini, J.-F.;Hoffman, J.;Huang, X.;Melichar, B.;Tahara, M. |
| 國立成功大學 |
2021 |
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
|
Even, C.;Wang, H.-M.;Li, S.-H.;Ngan, R.K.-C.;Dechaphunkul, A.;Zhang, L.;Yen, C.-J.;Chan, P.C.;Chakrabandhu, S.;Ma, B.B.Y.;Tanasanvimon, S.;Lee, V.H.F.;Lou, P.-J.;Li, Z.;Spira, A.I.;Sukari, A.;Guigay, J.;McCune, S.;Gonzalez-Maffe, J.;Szpakowski, Szpakowski S.;Yao, Yao Y.;Liang, H.;Mataraza, J.;Sechaud, R.;Manenti, L.;Lim, D.W.-T. |
| 國立成功大學 |
2021 |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu, A.X.;Finn, R.S.;Kang, Y.-K.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Motomura, K.;Ohno, I.;Daniele, B.;Vogel, A.;Yamashita, T.;Hsu, C.-H.;Gerken, Gerken G.;Bilbruck, J.;Hsu, Y.;Liang, K.;Widau, R.C.;Wang, C.;Abada, P.;Kudo, M. |
| 國立成功大學 |
2021 |
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
|
Chao, J.;Fuchs, C.S.;Shitara, K.;Tabernero, J.;Muro, K.;Van, Cutsem E.;Bang, Y.-J.;De, Vita F.;Landers, G.;Yen, C.-J.;Chau, I.;Elme, A.;Lee, J.;Özgüroǧlu, M.;Catenacci, D.;Yoon, H.H.;Chen, E.;Adelberg, D.;Shih, C.-S.;Shah, Shah S.;Bhagia, P.;Wainberg, Z.A. |
| 國立成功大學 |
2021 |
Clinical and immunologic responses to a B-Cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer—results from phase Ib trial IMU.ACS.001
|
Wiedermann, U.;Garner-Spitzer, E.;Chao, Y.;Maglakelidze, Maglakelidze M.;Bulat, I.;Dechaphunkul, A.;Arpornwirat, W.;Charoentum, Charoentum C.;Yen, C.-J.;Yau, T.C.;Tanasanvimon, S.;Maneechavakajorn, J.;Sookprasert, A.;Bai, L.-Y.;Chou, W.-C.;Ungtrakul, T.;Drinic, M.;Tobias, J.;Zielinski, C.C.;Chong, L.;Ede, N.J.;Marino, Marino M.T.;Good, A.J. |
| 國立成功大學 |
2021 |
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
|
Mai, H.-Q.;Chen, Q.-Y.;Chen, D.;Hu, C.;Yang, K.;Wen, J.;Li, J.;Shi, Y.-R.;Jin, F.;Xu, R.;Pan, J.;Qu, S.;Li, P.;Hu, C.;Liu, Y.-C.;Jiang, Y.;He, X.;Wang, H.-M.;Lim, W.-T.;Liao, W.;He, X.;Chen, X.;Liu, Z.;Yuan, X.;Li, Q.;Lin, X.;Jing, S.;Chen, Y.;Lu, Y.;Hsieh, C.-Y.;Yang, M.-H.;Yen, C.-J.;Samol, J.;Feng, H.;Yao, S.;Keegan, P.;Xu, R.-H. |
| 臺大學術典藏 |
2020-12-28T12:04:16Z |
Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults
|
Kuo H.-K.; Chen C.-Y.; Liu H.-M.; Yen C.-J.; Chang K.-J.; Chang C.-C.; Yu Y.-H.; Lin L.-Y.; HWANG, JUEY-JEN |
| 臺大學術典藏 |
2020-12-28T01:53:09Z |
Nociceptive transient receptor potential canonical 7?(TRPC7) mediates aging-associated tumorigenesis induced by ultraviolet B
|
Hsu, W.-L.;Tsai, M.-H.;Wu, C.-Y.;Liang, J.-L.;Lu, J.-H.;Kahle, J.S.;Yu, H.-S.;Yen, C.-J.;Yen, C.-T.;Hsieh, Y.-C.;Huang, Y.-Y.;Lin, L.-C.;Tsai, T.-F.;Chen, C.-H.;Yoshioka, T.; Hsu, W.-L.; Tsai, M.-H.; Wu, C.-Y.; Liang, J.-L.; Lu, J.-H.; Kahle, J.S.; Yu, H.-S.; Yen, C.-J.; Yen, C.-T.; Hsieh, Y.-C.; Huang, Y.-Y.; Lin, L.-C.; Tsai, T.-F.; Chen, C.-H.; Yoshioka, T.; CHEN-TUNG YEN |
| 臺大學術典藏 |
2020-12-24T08:38:30Z |
Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients
|
Lin Y.-F.; Lin Y.-F.;Chen Y.-M.;Hung K.-Y.;Chu T.-S.;Kan W.-C.;Huang C.-Y.;Lin S.-L.;Kao T.-W.;Huang J.-W.;Wen-Chih Chiang;Yen C.-J.;Tsai T.-J.;Wu K.-D.;Wu M.-S.; Wu M.-S.; Wu K.-D.; Tsai T.-J.; Yen C.-J.; Chen Y.-M.; Hung K.-Y.; Chu T.-S.; Kan W.-C.; Huang C.-Y.; Lin S.-L.; Kao T.-W.; Huang J.-W.; WEN-CHIH CHIANG |
| 臺大學術典藏 |
2020-12-24T08:11:52Z |
Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients
|
MING-SHIOU WU; Wu K.-D.; Tsai T.-J.; Chiang W.-C.; Yen C.-J.; Huang J.-W.; Kao T.-W.; Lin S.-L.; Huang C.-Y.; Kan W.-C.; Chu T.-S.; Hung K.-Y.; Chen Y.-M.; Lin Y.-F.; Lin Y.-F.;Chen Y.-M.;Hung K.-Y.;Chu T.-S.;Kan W.-C.;Huang C.-Y.;Lin S.-L.;Kao T.-W.;Huang J.-W.;Chiang W.-C.;Yen C.-J.;Tsai T.-J.;Wu K.-D.;Ming-Shiou Wu |
顯示項目 181-205 / 471 (共19頁)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每頁顯示[10|25|50]項目
|
